Subscribers to Growth Capitalist's premium research report on emerging growth company finance can download the November 18 issue now. Log in to download your copy here.
Don't subscribe yet? Register or email us for a 30-day free … Continue reading →
OncoMed Pharmaceuticals Raises $22.25M at 8% Premium from Celgene Corp. – OncoMed Pharmaceuticals Inc. (OMED) announced that it has raised $22,249,996 in a Common Stock transaction. The common stock was sold at $15.13 per share, an approximate 8% premium to the market price ($14.00) of OMED at … Continue reading →
DHT Holdings Raises $110M at 7% Discount via RS Platou Markets – DHT Holdings, Inc. (DHT) announced that it has raised $110,000,025 in a Common Stock transaction. The common stock was sold at $4.75 per share, an approximate 7% discount to the market price ($5.13) of DHT at deal announcement. RS … Continue reading →
Private funds received the same marketing freedoms as operating companies and startups when the Securities and Exchange Commission lifted the ban on general solicitation in September. But while small business proponents heralded the ban’s end as a transformative capital raising event, private … Continue reading →